Neowise Biotechnology develops TCR-T cell receptor-based therapies specifically targeting solid tumors by utilizing a proprietary antigen-receptor pairing database for efficient target screening and T cell engineering. This approach addresses the challenge of limited treatment options for solid tumors by providing highly specific T cells that recognize and attack tumor surface antigens.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors present a significant challenge in cancer treatment due to the limited availability of targeted therapies and the difficulty in identifying suitable tumor-specific antigens. Traditional treatment options often lack specificity, leading to off-target effects and reduced efficacy. The discovery and validation of target-TCR pairs for solid tumors remains a bottleneck in the development of effective TCR-T cell therapies.
Solution
Neowise Biotechnology is developing T cell receptor (TCR)-based immunotherapies specifically engineered to target solid tumors. The company utilizes a proprietary target-TCR pairing database and screening platform to identify and validate highly specific TCRs that recognize tumor-associated antigens. This approach enables the development of TCR-T cell therapies with enhanced tumor recognition and reduced off-target effects. By leveraging its expertise in TCR discovery and T cell engineering, Neowise aims to expand the treatment options available for patients with solid tumors.
Target Audience
The primary target audience includes patients with solid tumors who have limited treatment options, as well as oncologists and clinical researchers seeking novel immunotherapeutic approaches.
Features
- Proprietary target-TCR discovery and validation platform for identifying high-affinity TCRs
- Extensive database of target-TCR pairs specific to solid tumor antigens
- T cell engineering capabilities to generate TCR-T cells with enhanced tumor-killing activity
- GMP-grade manufacturing facility for producing clinical-grade TCR-T cell therapies
- Clinical trials evaluating the safety and efficacy of TCR-T cell therapies in patients with solid tumors